Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit of Merck & Co's gefapixant, which was filed for approval in March.

The signs of a dangerous blood clot can vary depending on its location. Some people may also not experience any symptoms.

If your allergies leave you feeling lightheaded or cause chest pain, alert your doctor immediately, Nagarajan said. It could ...

That response can lead to chronic inflammation ... Dr. Sairaman Nagarajan, a physician editor at The Merck Manuals and an adjunct faculty member at SUNY Downstate Health Sciences, was lead ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas ...

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other best ...